New and emerging therapies for acute myeloid leukaemia

Julian R. Davis, David J. Benjamin, Brian Jonas

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The treatment of acute myeloid leukemia (AML) has remained relatively unchanged for the past 3-4 decades with generally poor outcomes, especially in elderly populations unfit for intensive therapy. Recent advancements, however, have identified several cytogenetic and molecular markers that have not only improved prognostication but have also led to the development of several new targeted therapies for specific subpopulations. In 2017, the US Food and Drug Administration approved four new treatments with indications for fms like tyrosine kinase 3 (FLT3)-mutated AML (midostaurin), newly diagnosed or relapsed/refractory CD33+AML (gemtuzumab ozogamicin), newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (CPX-351) and relapsed/refractory AML with an isocitrate dehydrogenase (IDH)2 mutation (enasidenib). These newly approved therapies have demonstrated improved response in their target populations in several pivotal clinical trials with some also demonstrating improved overall survival. Additional novel therapies in development for AML include agents that target B cell lymphoma 2, FLT3, IDH1, the ubiquitination pathway, as well as cell therapy using engineered T cells with chimeric antigen receptors. This review provides a summary of the four newly approved therapies for AML, as well as several promising therapies currently in development.

Original languageEnglish (US)
JournalJournal of Investigative Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

fms-Like Tyrosine Kinase 3
4'-N-benzoylstaurosporine
Acute Myeloid Leukemia
Refractory materials
Isocitrate Dehydrogenase
Antigen Receptors
T-cells
Cells
Therapeutics
Health Services Needs and Demand
Ubiquitination
B-Cell Lymphoma
United States Food and Drug Administration
Cell- and Tissue-Based Therapy
Cytogenetics
Clinical Trials

Keywords

  • acute
  • clinical research
  • Leukemia
  • myeloid

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

New and emerging therapies for acute myeloid leukaemia. / Davis, Julian R.; Benjamin, David J.; Jonas, Brian.

In: Journal of Investigative Medicine, 01.01.2018.

Research output: Contribution to journalArticle

@article{e6a042a85e50476f8074b0869572ad61,
title = "New and emerging therapies for acute myeloid leukaemia",
abstract = "The treatment of acute myeloid leukemia (AML) has remained relatively unchanged for the past 3-4 decades with generally poor outcomes, especially in elderly populations unfit for intensive therapy. Recent advancements, however, have identified several cytogenetic and molecular markers that have not only improved prognostication but have also led to the development of several new targeted therapies for specific subpopulations. In 2017, the US Food and Drug Administration approved four new treatments with indications for fms like tyrosine kinase 3 (FLT3)-mutated AML (midostaurin), newly diagnosed or relapsed/refractory CD33+AML (gemtuzumab ozogamicin), newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (CPX-351) and relapsed/refractory AML with an isocitrate dehydrogenase (IDH)2 mutation (enasidenib). These newly approved therapies have demonstrated improved response in their target populations in several pivotal clinical trials with some also demonstrating improved overall survival. Additional novel therapies in development for AML include agents that target B cell lymphoma 2, FLT3, IDH1, the ubiquitination pathway, as well as cell therapy using engineered T cells with chimeric antigen receptors. This review provides a summary of the four newly approved therapies for AML, as well as several promising therapies currently in development.",
keywords = "acute, clinical research, Leukemia, myeloid",
author = "Davis, {Julian R.} and Benjamin, {David J.} and Brian Jonas",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/jim-2018-000807",
language = "English (US)",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - New and emerging therapies for acute myeloid leukaemia

AU - Davis, Julian R.

AU - Benjamin, David J.

AU - Jonas, Brian

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The treatment of acute myeloid leukemia (AML) has remained relatively unchanged for the past 3-4 decades with generally poor outcomes, especially in elderly populations unfit for intensive therapy. Recent advancements, however, have identified several cytogenetic and molecular markers that have not only improved prognostication but have also led to the development of several new targeted therapies for specific subpopulations. In 2017, the US Food and Drug Administration approved four new treatments with indications for fms like tyrosine kinase 3 (FLT3)-mutated AML (midostaurin), newly diagnosed or relapsed/refractory CD33+AML (gemtuzumab ozogamicin), newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (CPX-351) and relapsed/refractory AML with an isocitrate dehydrogenase (IDH)2 mutation (enasidenib). These newly approved therapies have demonstrated improved response in their target populations in several pivotal clinical trials with some also demonstrating improved overall survival. Additional novel therapies in development for AML include agents that target B cell lymphoma 2, FLT3, IDH1, the ubiquitination pathway, as well as cell therapy using engineered T cells with chimeric antigen receptors. This review provides a summary of the four newly approved therapies for AML, as well as several promising therapies currently in development.

AB - The treatment of acute myeloid leukemia (AML) has remained relatively unchanged for the past 3-4 decades with generally poor outcomes, especially in elderly populations unfit for intensive therapy. Recent advancements, however, have identified several cytogenetic and molecular markers that have not only improved prognostication but have also led to the development of several new targeted therapies for specific subpopulations. In 2017, the US Food and Drug Administration approved four new treatments with indications for fms like tyrosine kinase 3 (FLT3)-mutated AML (midostaurin), newly diagnosed or relapsed/refractory CD33+AML (gemtuzumab ozogamicin), newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (CPX-351) and relapsed/refractory AML with an isocitrate dehydrogenase (IDH)2 mutation (enasidenib). These newly approved therapies have demonstrated improved response in their target populations in several pivotal clinical trials with some also demonstrating improved overall survival. Additional novel therapies in development for AML include agents that target B cell lymphoma 2, FLT3, IDH1, the ubiquitination pathway, as well as cell therapy using engineered T cells with chimeric antigen receptors. This review provides a summary of the four newly approved therapies for AML, as well as several promising therapies currently in development.

KW - acute

KW - clinical research

KW - Leukemia

KW - myeloid

UR - http://www.scopus.com/inward/record.url?scp=85052640779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052640779&partnerID=8YFLogxK

U2 - 10.1136/jim-2018-000807

DO - 10.1136/jim-2018-000807

M3 - Article

C2 - 30127098

AN - SCOPUS:85052640779

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

ER -